BHWM
BBIO icon

Bay Harbor Wealth Management’s BridgeBio Pharma BBIO Stock Holding History

Bay Harbor Wealth Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.31K Buy
31
+7
+29% +$490 ﹤0.01% 615
2026
Q1 		$1.78K Buy
24
+8
+50% +$580 ﹤0.01% 596
2025
Q4 		$1.22K Buy
16
+4
+33% +$263 ﹤0.01% 586
2025
Q3 		$623 Buy
12
+4
+50% +$195 ﹤0.01% 649
2025
Q2 		$345 Buy
8
+5
+167% +$182 ﹤0.01% 754
2025
Q1 		$103 Buy
+3
New +$101 ﹤0.01% 872

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Bay Harbor Wealth Management's BBIO Position: Q2 2026 in Review

Bay Harbor Wealth Management increased its BridgeBio Pharma (BBIO) stake by 29% in Q2 2026, buying an estimated $490 and bringing the position to 31 shares worth $2.31K. The position accounts for ﹤0.01% of the portfolio, ranked #615.

Bay Harbor Wealth Management first reported a position in BBIO in Q1 2025 and has held it in 6 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Bay Harbor Wealth Management held 31 shares of BridgeBio Pharma worth $2.31K as of Q2 2026.
  • Bay Harbor Wealth Management bought 7 BridgeBio Pharma shares in Q2 2026, an estimated $490.
  • BridgeBio Pharma made up ﹤0.01% of Bay Harbor Wealth Management's portfolio in Q2 2026, its #615 holding.
  • Bay Harbor Wealth Management first reported a position in BridgeBio Pharma in Q1 2025 and has held it in 6 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Bay Harbor Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.